IL228405A0 - Methods for targeted treatment of degeneration of the frontotemporal lobe - Google Patents
Methods for targeted treatment of degeneration of the frontotemporal lobeInfo
- Publication number
- IL228405A0 IL228405A0 IL228405A IL22840513A IL228405A0 IL 228405 A0 IL228405 A0 IL 228405A0 IL 228405 A IL228405 A IL 228405A IL 22840513 A IL22840513 A IL 22840513A IL 228405 A0 IL228405 A0 IL 228405A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- targeted treatment
- frontotemporal lobar
- lobar degeneration
- degeneration
- Prior art date
Links
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 title 1
- 201000011240 Frontotemporal dementia Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467989P | 2011-03-26 | 2011-03-26 | |
| PCT/US2012/030527 WO2012135097A1 (en) | 2011-03-26 | 2012-03-26 | Methods of targeted treatment of frontotemporal lobar degeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL228405A0 true IL228405A0 (en) | 2013-12-31 |
Family
ID=45931040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL228405A IL228405A0 (en) | 2011-03-26 | 2013-09-12 | Methods for targeted treatment of degeneration of the frontotemporal lobe |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140179678A1 (https=) |
| EP (1) | EP2691099A1 (https=) |
| JP (2) | JP5995956B2 (https=) |
| CN (2) | CN103561747B (https=) |
| AR (1) | AR085572A1 (https=) |
| AU (1) | AU2012236852A1 (https=) |
| CA (1) | CA2831291A1 (https=) |
| IL (1) | IL228405A0 (https=) |
| MX (1) | MX2013011096A (https=) |
| RU (1) | RU2013147810A (https=) |
| TW (1) | TW201247205A (https=) |
| UY (1) | UY33973A (https=) |
| WO (1) | WO2012135097A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10149836B2 (en) | 2014-03-21 | 2018-12-11 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for frontotemporal dementia |
| US10189841B2 (en) | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| AR119149A1 (es) * | 2019-06-12 | 2021-11-24 | Arkuda Therapeutics | Derivados de isoquinolina como moduladores de la progranulina |
| US20230201269A1 (en) * | 2020-04-24 | 2023-06-29 | Spinalcyte, Llc | Treatment of frontotemporal dementia using fibroblasts and products thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| CN101573333B (zh) * | 2006-10-28 | 2013-06-12 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| US20090291444A1 (en) * | 2008-03-31 | 2009-11-26 | Jason Eriksen | Methods and materials for detecting and treating dementia |
| US20110288070A1 (en) * | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137499A1 (en) * | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
-
2012
- 2012-03-26 AR ARP120101007A patent/AR085572A1/es unknown
- 2012-03-26 JP JP2014502654A patent/JP5995956B2/ja not_active Expired - Fee Related
- 2012-03-26 MX MX2013011096A patent/MX2013011096A/es not_active Application Discontinuation
- 2012-03-26 CN CN201280025073.5A patent/CN103561747B/zh not_active Expired - Fee Related
- 2012-03-26 CN CN201610143729.3A patent/CN105748484A/zh active Pending
- 2012-03-26 TW TW101110441A patent/TW201247205A/zh unknown
- 2012-03-26 EP EP12712497.2A patent/EP2691099A1/en not_active Withdrawn
- 2012-03-26 US US14/007,572 patent/US20140179678A1/en not_active Abandoned
- 2012-03-26 CA CA2831291A patent/CA2831291A1/en not_active Abandoned
- 2012-03-26 WO PCT/US2012/030527 patent/WO2012135097A1/en not_active Ceased
- 2012-03-26 RU RU2013147810/15A patent/RU2013147810A/ru not_active Application Discontinuation
- 2012-03-26 UY UY0001033973A patent/UY33973A/es not_active Application Discontinuation
- 2012-03-26 AU AU2012236852A patent/AU2012236852A1/en not_active Abandoned
-
2013
- 2013-09-12 IL IL228405A patent/IL228405A0/en unknown
-
2016
- 2016-08-23 JP JP2016162758A patent/JP2017019826A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201247205A (en) | 2012-12-01 |
| JP2014511848A (ja) | 2014-05-19 |
| CN103561747A (zh) | 2014-02-05 |
| JP5995956B2 (ja) | 2016-09-21 |
| EP2691099A1 (en) | 2014-02-05 |
| CN105748484A (zh) | 2016-07-13 |
| CA2831291A1 (en) | 2012-10-04 |
| RU2013147810A (ru) | 2015-05-10 |
| US20140179678A1 (en) | 2014-06-26 |
| AU2012236852A1 (en) | 2013-09-26 |
| CN103561747B (zh) | 2016-04-06 |
| MX2013011096A (es) | 2014-06-06 |
| WO2012135097A1 (en) | 2012-10-04 |
| AR085572A1 (es) | 2013-10-09 |
| JP2017019826A (ja) | 2017-01-26 |
| UY33973A (es) | 2012-10-31 |
| NZ615177A (en) | 2016-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201110095D0 (en) | Method of treatment | |
| EP2773754A4 (en) | Methods of Treatment | |
| SG2014008080A (en) | Methods of treatment of retinal degeneration diseases | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| IL230433A0 (en) | Pain management methods | |
| IL260115A (en) | Methods for treating fibrosis (Leifat) | |
| ZA201309557B (en) | Methods of treatment for retinal diseases | |
| IL237772A0 (en) | Methods and preparations for the treatment of retinal degeneration | |
| IL239273A0 (en) | A method of treating diseases | |
| IL228405A0 (en) | Methods for targeted treatment of degeneration of the frontotemporal lobe | |
| GB201105523D0 (en) | Treatment method | |
| EP2791324A4 (en) | PROCESSING METHOD | |
| HK1194658A (en) | Methods of targeted treatment of frontotemporal lobar degeneration | |
| GB201117252D0 (en) | Improved treatment of hard surfaces | |
| EP2911662A4 (en) | METHOD OF TREATING A DISEASE | |
| GB201109737D0 (en) | Methods of treatment | |
| GB201110602D0 (en) | Methods of treatment | |
| GB201109509D0 (en) | Method of treatment | |
| GB201103044D0 (en) | Method of treatment | |
| GB201109266D0 (en) | Method of treatment | |
| GB201111530D0 (en) | Method of treatment | |
| ZA201404348B (en) | Treatment of seborrhoea | |
| GB201221032D0 (en) | Method of treatment | |
| GB201207894D0 (en) | Method of treatment | |
| PT2811993T (pt) | Métodos de tratamento da fibrose |